HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1865-1873

  Armenia, D ^a   Fabeni, L ^b   Alteri, C ^a   Di Pinto, D ^a   Di Carlo, D ^a   Bertoli, A ^a,c   Gori, C ^b   Carta, S ^b   Fedele, V ^b   Forbici, F ^b   D'Arrigo, R ^b   Svicher, V ^a   Berno, G ^b   Pizzi, D ^b   Nicastri, E ^b   Sarmati, L ^c   Pinnetti, C ^b   Ammassari, A ^b   D'Offizi, G ^b   Latini, A ^d   Andreoni, M ^c   Antinori, A ^b   Ceccherini Silberstein, F ^a   Perno, C F ^b   Santoro, M M ^a   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Dolutegravir; Drug resistance; Elvitegravir; HIV 1 genotyping; INSTI; Integrase; Low level viraemia; Raltegravir

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS 1 INTEGRASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INTEGRASE; INTEGRASE INHIBITOR; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS RNA; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; GENETIC DISTANCE; GENETIC PROCEDURES; GENOTYPE; GENOTYPIC RESISTANCE TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PHYLOGENY; TREATMENT DURATION; VIREMIA; VIRUS LOAD; VIRUS MUTATION; ADULT; EVALUATION STUDY; FEMALE; GENETICS; GENOTYPING TECHNIQUE; HIV INFECTIONS; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MISSENSE MUTATION; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VIROLOGY;

ADULT; FEMALE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIREMIA;

EID: 84930510324     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv029     Document Type: Article

References (47)

1. Rockstroh JK, DeJesus E, Lennox JL et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013; 63: 77-85.
2. Eron JJ, Cooper DA, Steigbigel RT et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013; 13: 587-96.
3. Messiaen P, Wensing AM, Fun A et al. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One 2013; 8: e52562.
4. Gottlieb GS, Smith RA, Dia Badiane NM et al. HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa. PLoS One 2011; 6: e22204.
5. Raffi F, Jaeger H, Quiros-Roldan E et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, noninferiority trial. Lancet Infect Dis 2013; 13: 927-35.
6. Clumeck N, Molina JM, Henry K et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65: e121-4.
7. DeJesus E, Rockstroh JK, Henry K et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavirboosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379: 2429-38.
8. Sax PE, DeJesus E, Mills A et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
9. Castagna A, Maggiolo F, Penco G et al. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210: 354-62.
10. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8.
11. US Food and Drug Administration. HIV/AIDS Update - Approval of Vitekta. http://content.govdelivery.com/accounts/USFDA/bulletins/d162bb.
12. Elion R, Molina JM, Ramon Arribas Lopez J et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr 2013; 63: 494-7.
13. Pozniak A, Markowitz M, Mills A et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of nonnucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis 2014; 14: 590-9.
14. Arribas JR, Pialoux G, Gathe J et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 2014; 14: 581-9.
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
16. Geretti AM, Armenia D, Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 2012; 25: 677-86.
17. Blanco JL, Varghese V, Rhee SY et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203: 1204-14.
18. Malet I, Fourati S, Morand-Joubert L et al. Risk factors for raltegravir resistance development in clinical practice. J Antimicrob Chemother 2012; 67: 2494-500.
19. Hurt CB, Sebastian J, Hicks CB et al. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2014; 58: 423-31.
20. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011; 13: 77-108.
21. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387-402.
22. European AIDS Clinical Society Guidelines (EACS). Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. Version 7.02, 2014. http://www.eacsociety.org/files/guidelines_english_71_141204.pdf.
23. Mackie N, Dustan S, McClure MO et al. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods 2004; 119: 73-8.
24. Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/mL. AIDS 2006; 20: 778-9.
25. Gonzalez-Serna A, Min JE, Woods C et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis 2014; 58: 1165-73.
26. Santoro MM, Fabeni L, Armenia D et al. Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis 2014; 58: 1156-64.
27. To SW, Chen JH, Wong KH et al. Performance comparison of an in-house integrase genotyping assay versus the ViroSeq Integra48, and study of HIV-1 integrase polymorphisms in Hong Kong. J Clin Virol 2013; 58: 299-302.
28. Swenson LC, Min JE,Woods CK et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS 2014; 28: 1125-34.
29. Delaugerre C, Gallien S, Flandre P et al. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One 2012; 7: e36673.
30. Gallien S, Delaugerre C, Charreau I et al. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS 2011; 25: 665-9.
31. Santoro MM, Armenia D, Alteri C et al. Impact of pre-therapy viral load on virological response tomodern first-line HAART. Antivir Ther 2013; 18: 867-76.
32. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-80.
33. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16: 111-20.
34. Wensing AM, Calvez V, Gunthard HF et al. 2014 update of the drug resistance mutations in HIV-1. Top Antivir Med 2014; 22: 642-50.
35. HIV-Stanford-Database. Integrase Inhibitor (INI) Resistance Notes. http://hivdb.stanford.edu/DR/INIResiNote.html.
36. Quashie PK, Mesplede T, Han YS et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705.
37. Quashie PK, Mesplede T, Han YS et al. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother 2013; 57: 6223-35.
38. Malet I, Fourati S, Charpentier C et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 2011; 66: 2827-30.
39. Marcelin AG, Delaugerre C, Beaudoux C et al. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. Int J Antimicrob Agents 2013; 42: 42-7.
40. Rusconi S, Vitiello P, Adorni F et al. Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. Clin Microbiol Infect 2013; 19: 936-42.
41. Capetti A, Meraviglia P, Landonio S et al. Four years data of raltegravirbased salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. Int J Antimicrob Agents 2014; 43: 189-94.
42. de Souza Cavalcanti J, de Paula Ferreira JL, Vidal JE et al. HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in Sao Paulo, Brazil. Int J Antimicrob Agents 2014; 43: 287-91.
43. Underwood MR, Johns BA, Sato A et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravirtreated adults. J Acquir Immune Defic Syndr 2012; 61: 297-301.
44. Armenia D, Vandenbroucke I, Fabeni L et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 2012; 205: 557-67.
45. Mukherjee R, Jensen ST, Male F et al. Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 2011; 25: 1951-9.
46. Canducci F, Ceresola ER, Boeri E et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011; 204: 1811-5.
47. Cozzi-Lepri A, Phillips AN, Ruiz L et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21: 721-32.